Economic assessment of thrombocytopenia: CATCH Registry.

Published

Journal Article

Thrombocytopenia is associated with increased patient risk. However, the costs of this complication are not well defined. This study assessed the impact of thrombocytopenia on in-hospital costs using results from CATCH, an observational study that examined 1988 consecutive patients receiving prolonged heparin therapy (> or =96 h). Thrombocytopenia was defined as: (group 1) an absolute reduction in platelet count to <150 x 10(9)/L; (group 2) a relative reduction in platelet count of >50% from admission levels; or (group 3) both criteria. We found that the development of thrombocytopenia was associated with significantly higher total in-hospital costs for all groups: (group 1) (difference, $8,222; 95% CI, $5,020-$11,425; P<.001); (group 2) (difference, $15,429; 95% CI, $7,472-$23,385; P<.001); and (group 3) (difference, $27,077; 95% CI, $22,901-$31,252; P<.001). However, in our adjusted model, longer lengths-of-stay and greater use of blood transfusions accounted for most incremental in-hospital cost differences.

Full Text

Duke Authors

Cited Authors

  • Eisenstein, EL; Honeycutt, EF; Anstrom, KJ; Becker, RC; Granger, CB; Rao, SV; Jolicoeur, ME; Ohman, EM; CATCH Investigators,

Published Date

  • June 2010

Published In

Volume / Issue

  • 34 / 3

Start / End Page

  • 379 - 386

PubMed ID

  • 20503623

Pubmed Central ID

  • 20503623

International Standard Serial Number (ISSN)

  • 0148-5598

Language

  • eng

Conference Location

  • United States